CNTX
Context Therapeutics Inc.
$0.65
+0.05 (+7.57%)
At close · Jul 2
Market Cap
$58.58M
Shares
91,879,177
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.65
Open$0.59
Day$0.59–0.68
52W$0.55–3.62
Avg vol 30d3.0M
Short int855K · 0.9% float · 1.0d
Short vol24%
Last earningsMar 22, 2023
DataOct 2021–Jul 2026
Filing10-Q · May 6
Equibles Rating
blended score · not investment advice
Overall
Buy
Technical · trend & momentum
Sell
◦
50 / 200-day cross
no cross
−
Price vs 200-day avg
−63% below
−
Price vs 50-day avg
−64% below
◦
RSI (14)
26 · oversold
+
MACD trend
positive
−
52-week position
4% · near low
Sentiment · smart money
Bullish
◦
Trend (MA cross)
50d $2 › 200d $2 — 50d above 200d
+
Institutional flow
+43% holders QoQ · +26 funds added
◦
Insider flow
No net insider activity over 90 days
+
Short interest
0.93% of float · ▼ -4.6% MoM · 1.0 days cover
◦
Volume signal
Volume near normal
+
Institution breadth
60 holders — near 3-yr high, broad support
Fundamentals
Strong
+
EPS growth
+17% Y/Y
−
Free cash flow
$-26.4M
+
Balance sheet
net cash $66.0M
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 6, 2026
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
−63% below
Bearish
Price vs 50-day avg
−64% below
Bearish
RSI (14)
26 · oversold
Neutral
MACD trend
positive
Bullish
52-week position
4% · near low
Bearish
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow
Accumulating
+43% holders QoQ · +26 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.93% of float · ▼ -4.6% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
60 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $1
Now $1 · 4%
52-wk high $4
vs 200-day avg -63%
vs 50-day avg -64%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CNTX
this stock
Context Therapeutics Inc.
|
$58.58M | -55.5% | — | — | 0.9% |
|
AKTX
Akari Therapeutics Plc
|
$953.21B | -9.9% | — | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$470.30B | -2.0% | +22179.2% | 957.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$134.02B | +16.5% | +46.2% | 31.3 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.80B | -15.1% | +20.8% | 16.3 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CNTX | +16.8% | -68.1% | -59.1% | +18.1% | -55.5% |
| SPY | +1.4% | -1.3% | +8.0% | -0.3% | +9.2% |
| vs SPY | +15.4% | -66.9% | -67.1% | +18.3% | -64.7% |